JW LIFESCIENCE CORPORATION
Financials
Valuation Metrics
JW LIFESCIENCE CORPORATION's Market Cap is ₩1739B. At end of 2025 it was ₩2035B. Ranked #932 of 2,421 in KR market (top 38%), #484 of 781 on KOSPI (top 62%), #103 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 173.86B KRW | KR#932/2,421 Sec#103/231 |
| Revenue | 253.71B KRW | KR#907/2,421 Sec#46/231 |
| Net Income | 26.02B KRW | KR#604/2,421 Sec#36/231 |
| Total Assets | 305.78B KRW | KR#1,025/2,421 Sec#68/231 |
| Net Assets | 226.76B KRW | KR#878/2,421 Sec#61/231 |
| Employees | 328 | KR#739/2,421 Sec#64/231 |
| Value | ||
| P/E | 6.68x | KR#532/2,421 Sec#23/231 |
| P/B | 0.77x | KR#1,212/2,421 Sec#72/231 |
| P/S | 0.69x | KR#1,128/2,421 Sec#56/231 |
| EV/EBITDA | 5.86x | KR#298/2,421 Sec#7/231 |
| FCF Yield | 16.09% | KR#412/2,421 Sec#10/231 |
| Profitability | ||
| ROE | 11.47% | KR#511/2,421 Sec#36/231 |
| ROA | 8.51% | KR#393/2,421 Sec#29/231 |
| Op. Margin | 13.14% | KR#364/2,421 Sec#33/231 |
| Revenue Growth | 4.13% | KR#1,254/2,421 Sec#127/231 |
| Earnings Growth | -47.42% | KR#1,049/2,421 Sec#69/231 |
| Financial Health | ||
| Debt Ratio | 34.85% | KR#690/2,421 Sec#85/231 |
| Total Debt | 30.50B KRW | KR#1,222/2,421 Sec#93/231 |
| FCF | 27.98B KRW | KR#431/2,421 Sec#23/231 |
| Cash | 9.00B KRW | KR#1,755/2,421 Sec#154/231 |
| Current Ratio | 1.25x | KR#1,448/2,421 Sec#152/231 |
| Net Debt/EBITDA | 0.64x | KR#698/2,421 Sec#44/231 |
| Dividend | ||
| Div. Yield | 5.02% | KR#276/2,421 Sec#7/231 |
| Div. Growth | 10.00% | KR#598/2,421 Sec#33/231 |
| Performance | ||
| 1Y Return | -8.04% | KR#923/2,421 Sec#57/231 |
| 1M Return | -1.88% | KR#1,464/2,421 Sec#114/231 |
| From 52W High | -29.52% | KR#515/2,421 Sec#30/231 |
| 1Y MDD | -30.84% | KR#275/2,421 Sec#17/231 |
| Trading | ||
| Volume | 9,390 shares | KR#1,938/2,421 Sec#189/231 |
| Trading Value | 103.5M KRW | KR#1,534/2,421 Sec#153/231 |
| Foreign Own. | 14.47% | KR#334/2,421 Sec#21/231 |
| Per Share | ||
| EPS | 1,643 KRW | KR#516/2,421 Sec#36/231 |
| BPS | 14,321 KRW | KR#725/2,421 Sec#49/231 |
Company Info
Established in 1994, this company produces and sells professional pharmaceutical infusions, including 3-Chamber nutritional infusions, which are manufactured by only a few companies. It has signed licensing-out and export contracts with global infusion manufacturer Baxter Corporation, becoming the first in Asia to obtain EU-GMP certification for its TPN production facility, recognizing its world-class production infrastructure. The HP Research Center is pursuing global growth through the development of non-PVC materials and the launch of TPN products, leveraging infusion-related technologies. JW Life Science is headquartered in Dangjin, Chungcheongnam-do.